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Why was the cohort set up?
The Finnish Gestational Diabetes (FinnGeDi) study is a
multicentre study that considered Finnish women who
gave birth in 2009–12, as well as their children and the
children’s fathers. The study period was after the introduc-
tion of new Finnish national comprehensive screening
guidelines for gestational diabetes mellitus (GDM).1 The
study consisted of two arms: a prospective clinical, genetic
case-control arm and a national register-based arm which
also includes data on children’s siblings and grandparents.
The FinnGeDi study was initiated to study different aspects
of GDM as diagnosed by comprehensive screening, which
was expected to increase the prevalence of GDM by identi-
fying previously undiagnosed cases.2
GDM is characterized by carbohydrate intolerance and/
or hyperglycaemia—with its onset or first recognition dur-
ing pregnancy, which is not overt type 1 diabetes nor type
2 diabetes (T2D).3 GDM affects 10–30% of all pregnan-
cies,4 recurs in 30–84% of women5 and is becoming more
common worldwide.6 It is frequently the first manifesta-
tion of an increased risk of diabetes, as up to two-thirds of
women with a history of GDM are estimated to develop
subsequent T2D.7–9 Women with a history of GDM also
have an increased risk for other metabolic and cardiovas-
cular diseases.9,10 Exposure to maternal hyperglycaemia
also impacts on the fetus: in addition to short-term conse-
quences—that is, macrosomia and neonatal hypoglycae-
mia11—children born from GDM pregnancies are at
increased risk of later T2D, metabolic syndrome, cardio-
vascular disease and cognitive impairment.12–14
GDM represents a part of a continuum of maternal
hyperglycaemia.2,11 There are no unanimously accepted in-
ternational criteria for diagnosis or screening,15 and guide-
lines vary considerably even between high-income
countries.15–17 Typically, GDM is diagnosed by an oral glu-
cose tolerance test (OGTT), which may be performed only
in women whose characteristics indicate an increased risk
(risk-factor-based screening) or in all or most pregnant
women (universal or comprehensive screening).15 The
FinnGeDi study was established after the national Finnish
Current Cure Guidelines were introduced in 2008 and com-
prehensive screening was recommended to replace the previ-
ous risk-factor-based screening.1 The study was expected to
identify new GDM cases in women without previous risk
factors and result in a higher GDM prevalence.2
The study aimed to identify potential genetic and epige-
netic biomarkers of GDM and assess putative risk factors
and clinical characteristics of GDM, enabling the charac-
terization of clinically identifiable and mechanistically
meaningful subgroups of the disorder. The short- and long-
term health of the mother and child are to be followed
up—that is, evaluating the consequences of GDM.
Furthermore, the incidence, distribution and consequences
of GDM are to be assessed in different socioeconomic and
demographic groups and across generations. To approach
these questions from different perspectives, two arms were
included in the FinnGeDi study: (i) a multicentre case-con-
trol arm including questionnaires, medical data, Medical
Birth Register (MBR) data and DNA samples from preg-
nant women with and without GDM, their children and
the children’s fathers; and (ii) the register-based arm using
the MBR and other Finnish comprehensive national regis-
ters. The study headquarters and database are located at
the National Institute for Health and Welfare (Finland),
which is the primary research institution of the study in ad-
dition to Oulu University Hospital. The study is funded by
the Academy of Finland and private foundations.
Who is in the cohort?
The cohort includes two arms: a case-control arm and a
register-based arm.
Case-control arm
The prospectively collected case-control cohort consists of
1146 pregnant women with GDM and 1066 women with-
out GDM, their children from the index pregnancy and the
children’s fathers. The flow chart of the study population
is presented in Figure 1. Women with GDM were recruited
from delivery units as they came to give birth, and the next
consenting woman without GDM was recruited as a con-
trol. The women were recruited between 1 February 2009
and 31 December 2012 at two tertiary-level hospitals
(Oulu University Hospital and Helsinki University
Hospital), which serve as secondary-level hospitals for
their region, and five secondary-level hospitals (in
Jyva¨skyla¨, Pori, Kajaani, Seina¨joki and Lappeenranta). All
the hospitals serve a specific geographical area. Women
with pre-pregnancy diabetes mellitus (DM) and multiple
pregnancies were excluded from the study. Women and
their spouses (the fathers of the children) signed informed
consent to the use of the growth and developmental data
of their children and to contact with the family later for
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follow-up studies. Blood samples (leukocyte DNA) were
drawn from both parents and from the umbilical cord after
delivery. Plasma from the umbilical cord sample was fro-
zen and stored at –80C. The parents completed back-
ground questionnaires—including information on family
and medical history and lifestyle factors (i.e. physical activ-
ity, diet and smoking). Maternal welfare clinical and hospi-
tal records were reviewed to confirm GDM diagnosis, and
detailed information on the women’s medical and obstetric
history, pregnancy complications and outcomes, labora-
tory measurements and the newborns’ health was
obtained. These data were combined with the MBR data.
For each delivery in Finland, a structured form for the
MBR is completed by the health personnel at the delivery
hospital within 7 days after delivery. It included data on
key obstetric, perinatal and neonatal outcomes. The MBR
was completed using data compiled by the Population
Register Centre on live births and by Statistics Finland on
stillbirths and infant deaths. Available data, including
blood samples, are described in detail in Tables 1 and 2.
The diagnosis of GDM was based on an abnormal
OGTT result during pregnancy. According to the Finnish
Current Care guidelines introduced in 2008, a 75 g 2-h
OGTT was recommended to be performed between the
24th and 28th gestational weeks in all women except those
with a very low risk of developing GDM. For high-risk
women, OGTT was recommended between 12 and
16 weeks of pregnancy, and if normal, a repeat test was
recommended between 24 and 28 weeks. The detailed
screening criteria are described in Table 3. The cut-off con-
centrations for venous plasma glucose were 5.3 mmol/l at
baseline (fasting glucose), 10.0 mmol/l at 1 h after glu-
cose intake or 8.6 mmol/l at 2 h after glucose intake.
GDM diagnosis was set if one or more glucose concentra-
tions exceeded the cut-off levels.1
Comparisons between women with or without GDM
and their spouses are shown in Table 4. As expected,
women with GDM were older, more often multiparous,
had higher prepregnancy body mass index (BMI) values
and often had chronic hypertension compared with con-
trols. Less upper tertiary-level educated women were in the
GDM group than in the control group. The groups were
comparable in terms of smoking before and during preg-
nancy. The incidence of gestational hypertension and pre-
eclampsia was higher in the women with GDM than in the
controls. For preeclampsia, the difference remained signifi-
cant even after adjustment for parity, maternal age and
pre-pregnancy BMI. Women with GDM had more induc-
tions of labour, caesarean sections and large-for-
gestational-age (LGA) newborns than controls. The
spouses of women with GDM were older and had higher
BMI than those of the control group. The screening rates
and glucose metabolism status of women with or without
GDM are given in Supplementary Table 1, available as
Supplementary data at IJE online.
Register-based arm
The register-based arm includes all 59 057 singleton preg-
nancies in women who gave birth in Finland in 2009. They
were identified through the MBR, which includes data on
whether OGTT was ‘performed (yes/no)’ and ‘abnormal
OGTTs (yes)’, if ‘insulin treatment was begun during preg-
nancy (yes)’ and ‘ICD-10 diagnosis codes of GDM’. The
accuracy of different variables and their combinations to
identify GDM cases was checked against laboratory-
Figure 1 Flow chart of women in the case-control arm. GDM, gestational diabetes mellitus; OGTT, oral glucose tolerance test.
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verified OGTT results. In addition, data from the Finnish
Care Register for Health Care (HILMO, former Hospital
Discharge Register) were tested to identify whether it im-
proved the accuracy of MBR variables (Supplementary
Data 1, available as Supplementary data at IJE online).
Based on these results, the accuracy of all three MBR varia-
bles mentioned above without HILMO variables was
found to be 94.3%, and they were used to identify GDM
cases from register data.
In 2009, a total of 6583 women (11.1%) were reported
to have GDM according to an ‘abnormal OGTT finding’
and/or ‘insulin initiation during pregnancy’ and/or ‘ICD-
10 diagnosis codes of GDM’ (ICD-10 code ‘O24.4’ or
‘O24.9’). Women with type 1 diabetes and T2D (n ¼ 449),
women with unclear diagnosis codes (n ¼ 2) and the latter
pregnancy of women with two pregnancies in 2009 (n¼19)
were excluded. All other women were chosen to serve as
controls (n ¼52 004) (Figure 2). Comparison of the base-
line clinical characteristics of women with GDM and con-
trols is shown in Supplementary Table 2A, available as
Supplementary data at IJE online. OGTT-verified controls
(n¼19 227) were found to have more background risk fac-
tors of GDM than controls without OGTT results (n¼32
777) (Supplementary Table 2B, available as Supplementary
data at IJE online). Women recognized as having GDM
through the MBR variable ‘ICD-10 diagnosis code of
GDM’ had higher parity than women who were recorded
to have ‘abnormal OGTT’ and/or ‘insulin initiation during
pregnancy’ in the MBR (Supplementary Table 2C, avail-
able as Supplementary data at IJE online).
The children born in 2009 serve as index children for
the identification of their siblings, fathers and grandpar-
ents. By using the unique personal identification code allo-
cated to each citizen and permanent resident of Finland,
data from various national registers (including data on, for
example, hospital discharges and diagnoses, reimburse-
ment for drugs, congenital anomalies, cancer diagnoses,
time and causes of deaths, social welfare benefits, educa-
tional degrees and occupation and matriculation
examination scores) can be linked to all family members
(Table 2). According to Finnish legislation, a register study
does not require permission from the study participants if
they are not contacted due to the study.
As the MBR does not include numerical OGTT data,
these data were obtained from hospital laboratory data-
bases for a subpopulation of 4954 women with singleton
pregnancies, who delivered in 2009 in six out of seven
study hospitals, with a total of 15 000 births per year.
These data were also used to validate the register data
(Supplementary Figure 1, available as Supplementary data
at IJE online).
How often have they been followed up?
In the case-control arm, the questionnaires, medical data
from hospital records and baseline register data were col-
lected at the time of enrolment in 2009–12. The study ena-
bles longitudinal follow-up for both women and children
by combining these data with data obtained from national
registers. The development and growth data of the children
will be collected later from child welfare clinic records. In
the register-based arm, the register data from MBR and the
OGTT results of the subpopulation of 4954 women were
collected at baseline in 2009. The first follow-up for the
both arms will be performed 7–10 years after the comple-
tion of the enrolment, and is planned to continue for deca-
des. Permissions for the register follow-ups will be updated
in 2024 and after that in 5-year periods. The linkage to
registers is presented in Table 2.
What has been measured?
The case-control cohort provides a large dataset from
questionnaires, hospital records and national registers,
combined with DNA trio samples from parents and chil-
dren to study novel genetic and epigenetic markers of
GDM (Tables 1 and 2)
Table 1. Number of available samples and data in the case-control arm
Sample/data GDM n¼1146 Control n ¼1066
Mother n (%) Father n (%) Child n (%) Mother n (%) Father n (%) Child n (%)
DNA 1044 (91.1) 910 (79.4) 1046 (91.3) 1013 (95.0) 893 (83.8) 957 (89.8)
Cord plasma 1051 (91.7) 967 (90.7)
Questionnaire 1030 (89.9) 599 (50.5) 935 (87.7) 586 (49.5)
Medical records 1117 (97.5) 1117 (97.5) 1042 (97.7) 1042 (97.7)
Medical Birth Register 1146 (100) 1066 (100)
DNA duo: DNA samples from mother and child; GDM n ¼ 971 (84.7%)/control n ¼ 927 (87.0%).
DNA trio: DNA samples from mother, father and child; GDM n ¼ 846 (73.8%)/control n ¼ 833 (78.1%).
GDM, gestational diabetes mellitus.
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The register-based arm provides data from MBR and
other national registers including registers maintained by
the National Institute of Health and Welfare, Statistics
Finland, Population Register Centre and Social Insurance
Institution of Finland (Table 2). Index mothers and their
children are identified from MBR records, and the fathers,
Table 2. Description of the data sources for both study arms
Register/source Type Data Time Subject Arm
Medical records Hospital and primary health care
records
Index pregnancy and delivery
data
OGTT values
Baseline Mo Case-control
Delivery data
Primary health care data
(growth, development, health)
Baseline
Follow-up
C Case-control
Questionnaire Background characteristics, life-
style factors, family history
Baseline Mo/Fa Case-control
National Institute for
Health and Welfare
Medical Birth Register Identification of the index
women and pregnancy data
Baseline Mo Case-control
Register-based
Previous and following
pregnancies
Baseline
Follow-up
Mo Case-control
Register-based
Births of the parents Baseline Mo/Fa Register-based
Register on congenital
malformations
Baseline
Follow-up
Mo/Fa/C
Mo/Fa/C/S
Case-control
Register-based
Care Register for Health Care
(HILMO)
Diagnoses
Procedures
Hospitalization
Baseline
Follow-up
Mo/Fa/C
Mo/Fa/C/S/G
Case-control
Register-based
Register of Primary Health Care
Visits (AvoHILMO)
Reasons for visits/
diagnosesProceduresOutpatie-
nt visits
Follow-up
(from 2011a)
Mo/Fa/C
Mo/Fa/C/S/G
Case-control
Register-based
Register of Social Welfare
Benefits
Years 2005-09 Mo/Fa Register-based
Cancer Register Baseline
Follow-up
Mo/Fa/C
Mo/Fa/C/G
Case-control
Register-based
Cancer Screening Registry Breast cancer screening Follow-up Mo Case-control
Register-based
Cervical cancer screening Mo Case-control
Register-based
Statistics Finland Educational degree and
occupation
Baseline Mo/Fa Register-based
Income and socioeconomic status Years 2005–09 Mo/Fa Register-based
Date and causes of death Follow-up Mo/Fa/C
Mo/Fa/C/S/G
Case-control
Register-based
Population Register
Centre
Identification of the father and
grandparents of index children
Baseline Fa/G Register-based
Identification of previous
children
Baseline Fa Register-based
Social Insurance
Institution of
Finland
Reimbursement of drugs Baseline
Follow-up
Mo/Fa/C
Mo/Fa/C/S/G
Case-control
Register-based
Purchase of medicine Follow-up Mo/C Case-control
Register-based
Prescription centre and archive Electronic prescriptions Follow-up
(from 2017a)
Mo/C Case-control
Register-based
Matriculation
Examination Board
Matriculation examination
scores
Mo/Fa Register-based
DNA sample data Epigenetic and genetic data Baseline Mo/Fa/C Case-control
Biobank Borealis Finnish Maternity Cohort
Biobank
Maternal first trimester serum
sample
Baseline Mo Case-control
Mo, index mother; Fa, index father; C, index child; S, siblings of the index child; G, grandparents of the index child; OGTT, oral glucose tolerance test
aYear when register was established.
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siblings and grandparents of the index children are identi-
fied from the Population Register Centre. The linkage of
these registers provides extensive data on diseases and
medical conditions with their complications and socioeco-
nomic adversities of the index families.
What has been found? Key findings and
publications
In the case-control arm, blood samples and data to study
epigenetics of GDM have been collected and discovery
analyses have been performed. The study will proceed to
epigenetic replication in other collaborative cohorts. The
results have not yet been published. In multivariate analy-
ses of clinical data, women’s own preterm birth, pre-preg-
nancy obesity, age 35 years and family history of GDM
or T2D were found to be independent risk factors for
GDM.18 In the register-based arm, an article focusing on
OGTT results after 24 weeks of pregnancy in the subpopu-
lation of 4033 women has been published.19
What are the main strengths and
weaknesses?
The main strengths of the population-based FinnGeDi co-
hort include prospective case-control samples from
women, children and their fathers to study genetics and
epigenetics of GDM; and the large and comprehensive
databases of clinical, lifestyle and register data of women
and children, with possibilities of longitudinal follow-up.
The use of different registers enables a multifaceted assess-
ment of the underlying socioeconomic and educational
background which may affect the prevalence and conse-
quences of GDM. The extension of data collection to the
children’s grandparents will contribute to the assessment
of intergenerational effects on GDM.
In the case-control arm, OGTT was performed in 672
of the 1066 women (62.8%) in the control group. A total
of 319 (81%) of those 394 women without OGTT did not
enter the screening because they were estimated to be at
very low risk of developing GDM according to the national
guidelines.1 Clinical characteristics of the women without
OGTT are detailed in Supplementary Table 3, available as
Supplementary data at IJE online.
In the register-based arm, GDM status is based on regis-
ter data, the validity of which to identify GDM has been
evaluated as high (Supplementary Data 1, available as
Supplementary data at IJE online). In general, the quality
of Finnish national registers, especially MBR, is high and
the coverage complete.20,21 In the control group, only one-
third of women were verified to have normal OGTT results
(Figure 2). However, controls without OGTT results were
found to have less GDM risk factors than controls having
normal OGTT results (Supplementary Table 2B, available
as Supplementary data at IJE online).
The use of comprehensive screening has resulted in an
increase in the incidence of GDM during recent years.22,23
The screening frequency has increased from 51.4% in
2009–12 to 66.0% in 2018, and the prevalence of GDM
increased from 11.3% to 21.3%, respectively.24 Thus,
some women with GDM remained undiagnosed when our
study was conducted.
Can I get hold of the data? Where can I find
out more?
Access to clinical data is regulated by ethics approvals and
individual consent. Access to registry data is subject to per-
mission from the registry authorities. For enquiries regard-
ing possible collaboration, please contact FinnGeDi’s
principal investigator and study coordinator, Adjunct
Professor Marja Va¨a¨ra¨sma¨ki, MD, PhD: [marja.
Table 3. Current Care Guideline 2007 for the screening of gestational diabetes mellitus using oral glucose tolerance test in
Finland (Current Care Guideline: Gestational diabetes 2007)1
Screening Pregnancy weeks Criteria
OGTT 12–16 Previous GDM diagnosis
Prepregnancy BMI 35 kg/m2
Glucosuria in early pregnancy
Oral glucocorticoid medication
Family history of T2D (parents, grandparents, siblings and children)
Polycystic ovary sydrome
OGTT 24–28 Recommended to be performed for all pregnant women (exceptions detailed above)
No OGTT Primiparous: age <25 years, pre-pregnancy BMI<25 kg/m2 and no family history of T2D
Multiparous: age <40 years, pre-pregnancy BMI <25 kg/m2 and no previous GDM diagnosis or macrosomia
OGTT, oral glucose tolerance test; GDM, gestational diabetes mellitus; BMI, body mass index; T2D, type 2 diabetes mellitus.
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Table 4. Maternal, neonatal and paternal characteristics of participants in the case-control arm
GDM n ¼1146 Control n¼1066 P-valuea P-valueb
Maternal characteristics
Age at delivery, years 32.16 5.4 29.66 5.2 <0.001
Gravity, n 1.96 2.5 1.66 2.2 <0.001
Parity, n 1.36 2.0 1.16 1.8 0.014
Primiparous, n (%) 482 (42.1%) 520 (48.8%) 0.002
Weight, kg (self-reported, pre-pregnancy) 76.66 17.2 (1145) 64.86 12.4 <0.001 <0.001c
Height, m (self-reported) 164.86 5.8 165.56 5.9 0.005
BMI, kg/m2 (self-reported, pre-pregnancy) 28.26 6.1 (1145) 23.66 4.2 <0.001 <0.001c
Education % (self-reported) (1030) (935) 0.014
Basic or less, n 68 (6.6%) 42 (4.5%)
Secondary, n 486 (47.2%) 426 (45.6%)
Lower-level tertiary, n 270 (26.2%) 231 (24.7%)
Upper-level tertiary, n 206 (20.0%) 236 (25.2%)
Smoking before pregnancy, n (%) 340 (31.1%) (1094) 298 (30.1%) (990) 0.629
Smoking during pregnancy, n (%) 191 (16.7%) (1142) 161 (15.1%) (1065) 0.303
Gestational weight gain, kgd 12.36 5.8 (1055) 14.86 5.1 (1032) <0.001 <0.001c
Excess gestational weight gaine, n (%) 521 (49.4%) 470 (45.5%) 0.079 0.006c
Chronic hypertension, n (%)f 181 (15.8%) (1144) 54 (5.1%) <0.001 0.011g
Gestational hypertension, n (%)h 235 (20.5%) (1144) 151 (14.2%) <0.001 0.134g
Preeclampsia, n (%)i 70 (6.1%) (1144) 28 (2.6%) <0.001 0.016g
Induced labour, n (%) 515 (44.9%) 342 (32.1%) <0.001 0.012g
Gestational weeks at delivery 39.66 1.4 40.16 1.4 <0.001 <0.001g
<37 weeks, n (%) 41 (3.6%) 23 (2.2%) 0.046 0.302j
42 weeks, n (%) 16 (1.4%) 30 (2.8%) 0.020 0.012j
Mode of delivery, n (%)
Vaginal, n (%) 912 (79.6%) 923 (86.6%) <0.001
Vacuum extraction, n (%) 109 (9.5%) 129 (12.1%) 0.050 0.228
Caesarean section 234 (20.4%) 143 (13.4%) <0.001
Neonatal characteristics
Five-minute Apgar points <7, n (%) 26 (2.6%) (999) 20 (2.1%) (937) 0.499
Shoulder dystocia, n (%) 5 (0.4%) 4 (0.4%) 0.822
Erb’s palsy, n (%) 1 (0.1%) (0.0%) 0.355
Birthweight, g 36476 507 35706 496 <0.001 <0.001k
Relative birthweight, SD 0.26 1.1 0.16 1.0 <0.001 <0.001k
Birthweight  4500 g, n (%) 33 (2.9%) 24 (2.3%) 0.351
LGA, n (%) 64 (5.6%) 28 (2.6%) <0.001 0.214g
SGA, n (%) 21 (1.8%) 34 (3.2%) 0.041 0.240g
Paternal characteristics
Age, years 33.96 6.2 (984) 31.56 5.7 (933) <0.001
BMI, kg/m2 (self-reported) 27.06 3.9 (591) 26.26 3.7 (578) <0.001
Data are presented as mean 6 SD or as number (percentages).
GDM, gestational diabetes mellitus; BMI, body mass index; LGA, large for gestational age (birthweight  2 SD); SGA, small for gestational age (birthweight
2 SD).
aUnadjusted P-values based on Student’s t test or v2 test.
bAdjusted P-values based on logistic regression.
cAdjusted for parity and mother’s age at birth.
dDifference of (self-reported) pre-pregnancy weight and weight at the last antenatal visit at 35 gestational weeks or later.
eExcess gestational weight gain based on Institute of Medicine 2009 criteria.
fSystolic blood pressure  140 mmHg and/or diastolic blood pressure  90 mmHg detected before 20 weeks of gestation.
gAdjusted for parity, mother’s age at birth and pre-pregnancy BMI.
hBlood pressure  140/90 mmHg, no proteinuria.
iBlood pressure  140/90 mmHg and proteinuria ( 0.3 g/24 h or two  1þ readings on a dipstick).
jAdjusted for parity, mother’s age at birth, pre-pregnancy BMI, hypertensive pregnancy complications and induction of labour (yes/no).
kAdjusted for parity, mother’s age at birth, gestational weeks, pre-pregnancy BMI and hypertensive pregnancy complications.
763e International Journal of Epidemiology, 2020, Vol. 49, No. 3
D
ow
nloaded from
 https://academ
ic.oup.com
/ije/article/49/3/762/5831097 by guest on 26 August 2020
vaarasmaki@oulu.fi] or Marja Va¨a¨ra¨sma¨ki, Oulu
University Hospital, Department of Obstetrics and
Gynaecology, PO Box 23, 90029 OYS, Oulu, Finland.
Supplementary Data
Supplementary data are available at IJE online.
Funding
The study is funded by Academy of Finland, Diabetes Research
Foundation, Foundation for Pediatric Research, Juho Vainio
Foundation, Novo Nordisk Foundation, Signe and Ane Gyllenberg
Foundation, Sigrid Juse´lius Foundation, Yrjo¨ Jahnsson Foundation,
Finnish Medical Foundation, Research Funds of Oulu University
Hospital (state grants), Research Funds of Helsinki University
Hospital (state grants), Medical Research Center Oulu and National
Institute for Health and Welfare (Finland).
Acknowledgements
Statistician Aini Bloigu is acknowledged for advice with data extrac-
tion and statistical analyses. Research staff members Susanna
Hamari, Riitta Kokko, Jenni Kovalainen, Anu Ojala, Sanni
Paloviita, Saara Peuhkuri, Hanna Valtonen and Raili Voittonen de-
serve gratitude for data extraction. Nurse coordinator Tiina
Kemppainen and research nurse Sarianna Vaara are acknowledged
for help with practical arrangements. We are also grateful to the
staff in the participating hospitals for collaboration: Piia
Ja¨a¨skela¨inen, Tarja Pulkkinen, Sirkka-Liisa Uusi-Rasi, Marika
Nieminen, Kati Kuhmonen, Sirpa Valpas and Teija Karkkulainen.
Conflict of Interest
None declared.
Figure 2 Flow chart of women in the register-based arm according to the Medical Birth Register 2009. Number of women (% of all 59 057 singleton
pregnancies). DM, diabetes; OGTT, oral glucose tolerance test; GDM, gestational diabetes mellitus.
Profile in a nutshell
• The FinnGeDi cohort was set up to provide a data-
base combining detailed clinical data and DNA trio
samples from mother, father and child to study ge-
netics, epigenetics, phenotype and long-term conse-
quences of GDM diagnosed using the new compre-
hensive screening guidelines.
• The cohort is based at the National Institute for
Health and Welfare (Oulu, Finland).
• The case-control cohort was recruited in 2009–12
and includes 1146 women with GDM and 1066 non-
diabetic controls aged 17–48 years, their children
and the children’s fathers.
• The register-based cohort consists of Finnish fam-
ilies where a mother gave birth in 2009 (n ¼ 59 057
singleton pregnancies). This cohort includes 6583
women (11.1%) with GDM.
• The main categories of data were blood samples
from parents and children, clinical data from hospital
and maternal welfare clinic records, register data
from national registers and self-reported lifestyle
and medical and family history data from
questionnaires.
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• Follow-up data collection will be performed 7–10
years after the end of the recruitment for both
cohorts, and is planned to continue for decades.
This will include the linkage of baseline data to na-
tional registers—for example, hospital discharge di-
agnoses, data on reimbursement for and purchase
of drugs and time and causes of deaths. Registers
are updated annually.
• The data cannot be provided as open access due to
strict national data protection regulations, but we
welcome collaboration. The use of registry data
requires study permission from all national registry
authorities. Requests may be addressed to [marja.
vaarasmaki@oulu.fi].
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